The U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on March 16, 2017 at the USPTO Headquarters (Alexandria, VA). The agenda for the meeting is as follows:
• Welcoming and Opening Remarks (10:00 - 10:10 am EDT) -- Jerry Lorengo, Director, TC1600, USPTO; Daniel Sullivan, Director, TC1600, USPTO; and Wanda Walker, Director, TC1600, USPTO
• Rationale Statements in 35 U.S.C. 103 (10:10 - 11:10 am) -- Cassandra Spyrou, Supervisory Review Quality Assurance Specialist, OPQA, USPTO
• The Role of Inherency in Making an Obviousness Determination (11:10 - 12:00 pm) -- William Smith, Of Counsel, BakerHostetler
• Lunch (12:00 pm - 1:00 pm)
• 37 CFR §1.132 Practice, Unexpected Results (1:00 - 1:40 pm) -- Scarlett Goon, QAS, TC1600, USPTO
• Range Analysis (1:40 - 2:40 pm) -- Jean Witz, SPE, CRU, USPTO
• Break (2:40 - 2:50 pm)
• Interview Practice (A Practitioner’s Perspective) (2:50 - 3:50 pm) -- Charles Andres, Associate, Patent and Innovation, WSGR
• Interview Training (USPTO) (3:50 - 4:30 pm) -- Frederick Krass, SPE, TC1600, USPTO
• Closing Remarks (4:30 - 4:40 pm) – Directors, TC1600, USPTO
Additional information regarding the BCP customer partnership meeting, including registration information for those wishing to attend the meeting or register for online participation, can be found here.
Comments